Key result
Succinobucol fails to reduce cardiovascular clinical endpoints in Phase III trials despite favorable preclinical properties.
Answers are grounded in this paper and cite their sources.
BACKGROUND: Succinobucol (AGI-1067) was developed as a probucol derivative with anti-inflammatory and antioxidant properties. It has undergone Phase III clinical trials to determine its place in the treatment of atherosclerotic disease. OBJECTIVE: This paper reviews the available history, pharmacology and preclinical and clinical trial data of succinobucol. METHODS: Data were compiled following review of publications indexed in Medline and International Pharmaceutical Abstracts, industry media releases and relevant bibliographies. RESULTS/CONCLUSION: In preclinical studies, succinobucol exhibited antioxidant, anti-inflammatory, antihyperglycemic and antiplatelet properties; however, these effects have not resulted in a reduction in cardiovascular clinical end points in clinical trials. Although proposed antihyperglycemic effects are being investigated, safety concerns and lack of clear cardiovascular benefit may limit its clinical use as an antihyperglycemic agent.
No takes yet. Share an insight, caveat, or question.
Muldrew et al. (2009) conducted a review in Atherosclerotic disease. Succinobucol (AGI-1067) was evaluated on Cardiovascular clinical end points. Succinobucol did not reduce cardiovascular clinical endpoints in Phase III clinical trials despite preclinical antioxidant, anti-inflammatory, and antihyperglycemic properties.
Synapse has enriched 10 related papers. Consider them for comparative context: